TransMedics (TMDX) director Stephanie Lovell sells 1,193 common shares in open-market trade

Rhea-AI Filing Summary

TransMedics Group, Inc. director Stephanie Lovell reported an open-market sale of common stock. On March 4, 2026, she sold 1,193 shares of TransMedics common stock at a price of $149.62 per share. After this transaction, she directly owned 2,866 shares of the company’s common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lovell Stephanie

(Last) (First) (Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER MA 01810

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S		1,193	D	$149.62	2,866	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	By: /s/ Gerardo Hernandez, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TransMedics (TMDX) director Stephanie Lovell report?

Stephanie Lovell reported an open-market sale of TransMedics common stock. She sold 1,193 shares of common stock in a single transaction and continues to hold shares directly following this sale as disclosed in the Form 4.

How many TransMedics (TMDX) shares did Stephanie Lovell sell and at what price?

She sold 1,193 shares of TransMedics common stock at a price of $149.62 per share. This was a single reported transaction classified as a sale in the open market or a private transaction under SEC Form 4 rules.

How many TransMedics (TMDX) shares does Stephanie Lovell own after the sale?

After the reported sale, Stephanie Lovell directly owned 2,866 shares of TransMedics common stock. The Form 4 indicates this post-transaction balance as her direct ownership position, reflecting the reduction from the 1,193 shares sold.

What is Stephanie Lovell’s role at TransMedics (TMDX) in this Form 4 filing?

In this Form 4, Stephanie Lovell is identified as a director of TransMedics Group, Inc. The filing indicates she is not listed as an officer or ten percent owner, with her position limited to board-level responsibilities in the disclosure.

Was Stephanie Lovell’s TransMedics (TMDX) transaction a direct or indirect ownership change?

The transaction involved directly held shares of TransMedics common stock. The Form 4 describes the ownership type as direct, with no nature-of-ownership footnote indicating trusts, partnerships, or other indirect holding entities for the 1,193 shares sold.

How is Stephanie Lovell’s TransMedics (TMDX) sale classified under SEC transaction codes?

Her sale is coded as “S,” meaning a sale in the open market or a private transaction. The filing further characterizes it as an open-market sale of common stock, consistent with standard SEC Form 4 transaction code descriptions.